South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot
24/11/2021 09:00
BENGALURU, Nov 24 (Reuters) - Indian drugmaker Cadila Healthcare CADI.NS said on Wednesday it had entered into a manufacturing and technology transfer agreement for its DNA COVID-19 vaccine with South Korea's Enzychem Lifesciences 183490.KQ . (Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Arun Koyyur) ((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))
Recent news on Enzychem Lifesciences
See all newsBrief: Enzychem Lifesciences To Divest 8 Billion Won Worth Of Own Shares
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot